Peijia Medical has received regulatory approval from the National Medical Products Administration of China for the TaurusTrio Transcatheter Aortic Valve system, a dedicated device for the treatment of native symptomatic severe aortic regurgitation. Developed under an exclusive license from JenaValve Technology, the system is based on the latter’s Trilogy Transcatheter Heart Valve platform and represents the first approved transcatheter aortic valve replacement system in China designed specifically for non-calcified aortic regurgitation anatomy.

This approval marks a significant development in China’s structural heart landscape, where device-based options for pure aortic regurgitation have historically been limited. With the TaurusTrio system, physicians will gain access to a leaflet-engaging transcatheter device that targets a longstanding treatment gap in patients who are poor surgical candidates.

Aortic regurgitation has lacked a transcatheter solution until now

For years, patients with aortic regurgitation in China have faced a clinical dilemma. While transcatheter aortic valve replacement has become the standard of care for aortic stenosis, its application in aortic regurgitation has remained off-label, suboptimal, or clinically unsuitable due to anatomical challenges. Unlike aortic stenosis, where calcification helps anchor the transcatheter valve, aortic regurgitation typically presents with soft, non-calcified leaflets. This makes valve anchoring unstable, leading to high rates of valve embolization, residual leak, or need for surgical bailout.

Peijia Medical’s TaurusTrio system directly addresses this challenge by employing JenaValve’s proprietary locator technology. Rather than relying on calcium for anchoring, the device engages the native leaflets and achieves commissural alignment. This design enables the valve to remain stable in non-calcified anatomy, potentially expanding the treatable patient population and reducing procedural risks. It also avoids the need for additional anchoring devices or embolic protection measures that are often required in off-label AR procedures.

Early clinical results point to strong safety and performance profile

The one-year results from the ALTER-AR clinical study provide the strongest validation to date for the TaurusTrio system in real-world use. The study reported a technical success rate of over 99 percent, with zero all-cause mortality at 30 days and a relatively low one-year mortality rate of 2.6 percent. Importantly, there were no cases of moderate or greater paravalvular leak at the one-year mark, a key endpoint in evaluating valve competence in AR.

In terms of functional improvement, nearly 92 percent of patients moved to New York Heart Association class I or II at six months, indicating meaningful recovery in cardiac performance. Measures of cardiac remodeling such as left ventricular end-diastolic volume and left ventricular mass also showed significant reversal, suggesting that the valve not only treats the immediate hemodynamic dysfunction but also enables longer-term myocardial recovery.

Clinicians tracking the space will likely view these results as a major advancement over current practice, where conservative management or off-label TAVR use offers inconsistent results. Still, questions remain about performance in more complex anatomies or lower-risk patient populations. Additional post-marketing surveillance will be needed to confirm these early benefits at scale.

China’s regulatory greenlight signals a shift in high-risk device evaluation

The approval of TaurusTrio also reflects an evolving regulatory philosophy within the National Medical Products Administration. High-risk cardiovascular devices, particularly those with Western lineage or foreign IP, have historically faced long timelines in China. Peijia Medical’s successful navigation of this pathway indicates that the NMPA is becoming more receptive to platform technologies that combine global innovation with domestic manufacturing and adaptation.

By partnering with JenaValve and integrating its technology into a Chinese regulatory and clinical context, Peijia Medical has demonstrated a hybrid model that may become more common in China’s medtech sector. Instead of merely acting as distributors or importers, domestic firms are now taking the lead in localizing and commercializing advanced technologies through exclusive licensing or co-development arrangements.

Industry observers suggest that this could encourage other companies with validated platforms to pursue similar partnerships, especially in underpenetrated indications such as aortic regurgitation, mitral repair, or tricuspid intervention. This approach also aligns with broader national goals to build indigenous innovation capabilities while still leveraging international expertise.

A potential commercial moat in an underserved and unsegmented market

TaurusTrio’s approval gives Peijia Medical first-mover advantage in what remains a largely untapped procedural market. While aortic stenosis has a well-defined device ecosystem, including options from Edwards Lifesciences, Medtronic, and domestic competitors, aortic regurgitation has remained an orphan indication from a commercial standpoint.

JenaValve’s Trilogy system has already demonstrated commercial viability in Europe, with more than 1,000 procedures performed under CE Mark. The ALIGN-AR study published in The Lancet and presented at PCR London Valves has further solidified its role in high-risk patients. Peijia Medical’s TaurusTrio, as the localized variant of this platform, now has the opportunity to define procedural norms and build clinical momentum in China before rivals can respond.

The company also benefits from a broader product portfolio that includes four TAVR systems and nearly 20 registered neurointerventional devices, giving it cross-specialty access and potential synergy in distribution. If TaurusTrio can secure early reimbursement inclusion and gain procedural traction among interventional cardiologists, Peijia Medical could lock in a durable competitive position.

Unmet needs, patient segmentation, and device-specific training will shape adoption

Despite the promising data, TaurusTrio’s real-world uptake will hinge on several practical factors. First, the identification of ideal patient subsets will be essential. While the device is approved for native symptomatic severe AR, clinicians will need to stratify patients by leaflet morphology, aortic root dimensions, and comorbidities to ensure procedural safety and durability.

Second, device-specific training will be critical. TaurusTrio employs a fundamentally different anchoring mechanism compared to conventional TAVR systems. Interventionalists will need to be trained not only on the deployment sequence but also on case selection, imaging, and bailout strategies. Peijia Medical will likely need to invest in proctorship programs, simulation labs, and peer-to-peer networks to build confidence across centers.

Finally, scalability will depend on manufacturing throughput and cost-effectiveness. As with any complex implantable device, consistency in quality and supply chain management will determine whether the company can meet anticipated demand while controlling production costs. Whether TaurusTrio becomes a niche solution or a volume driver will depend on these execution details.

Competitive response will likely focus on design iteration and data depth

Rival device manufacturers, both domestic and global, are unlikely to ignore the implications of TaurusTrio’s approval. Companies with existing TAVR platforms may begin modifying their designs to better accommodate leaflet engagement or explore repositionable, recapturable devices tailored to aortic regurgitation. Others may invest in longer clinical trials to differentiate on durability or safety in mixed-valve disease cohorts.

Some firms may even pursue next-generation anchoring technologies, such as bioadhesive pads, shape-memory scaffolds, or electromechanical expansion mechanisms, that offer more versatility across anatomical variants. These developments will likely accelerate if early TaurusTrio adoption signals commercial viability for AR-specific devices.

At the same time, regulators may face pressure to clarify labeling policies for off-label use of existing TAVR devices in AR. This could result in more structured guidance or new registries tracking real-world outcomes across devices and indications.

A new chapter for structural heart innovation in China?

TaurusTrio’s approval represents a convergence of clinical need, technology licensing, and regulatory evolution. It introduces a transcatheter therapy built specifically for an underserved indication and does so through a partnership model that bridges global IP with local execution. For Peijia Medical, it validates a strategy centered on high-impact innovation rather than me-too devices.

For the Chinese medical device ecosystem, it sends a clear message that local firms can move beyond copycat development and into genuine leadership roles in cardiovascular intervention. The next phase will depend on how well this approval translates into adoption, outcomes, and patient access. But for now, TaurusTrio gives the field of aortic regurgitation a long-awaited purpose-built tool—and gives China a new foothold in the next generation of structural heart care.

  ALTER-AR, aortic regurgitation, AR device, JenaValve Technology, NMPA approval, Peijia Medical, TaurusTrio, TAVR, transcatheter valve, Trilogy THV